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A fast and sensitive chiral capillary electrophoresis method has been developed to determine
levornidazole and its enantiomeric impurity at a 0.05% level in levornidazole injection solution. Several
chemical and instrumental parameters which have an effect on chiral separation were investigated,
including chiral selectors, buffer composition and pH, applied voltage, capillary length, temperature
and rinsing procedure. After optimizing all the effective parameters, the ideal separation conditions
were 20 mM Tris phosphate buffer at pH 2.1, containing 2.0% (w/v) sulfated-a-cyclodextrin with short
end injection at 0.5 psi for 5.0 s. Online UV detection was performed at 277 nm. A voltage of 30 kV was
applied and the capillary temperature was kept at 25 1C. 2,4,6-triaminopyrimidine was chosen as
internal standard to improve the injection precision. The total analysis time is less than 7 min, which is
faster than the existing chiral HPLC method (65 min). The validation of the method was performed in
terms of factorial analysis, stability of the solution, different cyclodextrin batches study, selectivity,
linearity (from 2.5 mg/mL to 6000 mg/mL, y¼0.0015 xþ0.0304; R2¼0.9999 and the residuals were
randomly scattered around 0), LOD and LOQ (0.3 and 1.0 mg/mL, respectively), precision and accuracy.
The proposed method was then applied to the enantiomeric purity control of the starting material and
injection solution of levornidazole (0.5 mg/100 mL).
& 2012 Elsevier B.V. All rights reserved.1. Introduction
Levornidazole ((S)-(-)-1-chloro-3-(-2-methyl-5-nitroimidazole-
1-yl) propan-2-ol, see Fig. 1), the S-enantiomer of ornidazole,
has been produced as a second generation single-enantiomer
drug of ornidazole. Ornidazole is used for the treatment and
prophylaxis of infections caused by anaerobic and microaerophi-
lic protozoa and bacteria [1–3]. By reduction of the nitro group to
a more reactive amine group, the compound attacks the microbial
DNA and leads to degradation of existing DNA [4–6]. The main
side effects of ornidazole are nausea, vomiting, spermatotoxicity
and central nerve toxicity [3]. Levornidazole has been observed toll rights reserved.
, cyclodextrins; S-b-CD, sul-
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en.be (A. Van Schepdael).have similar clinical efficacy as ornidazole, but with fewer
associated adverse drug reactions. Several papers related to
different pharmacological activities and toxicity of the two
enantiomers of ornidazole have appeared [3,7–11]. Therefore,
the R-enantiomer of ornidazole should be considered as an
enantiomeric impurity in starting material and pharmaceutical
formulations of levornidazole.
Chiral separations performed by HPLC remain the workhorse
of all enantioseparations, especially on the preparative scale. The
use of polysaccharide and cyclodextrin chiral stationary phases
(CSPs) continues to dominate the majority of all LC separations
using CSPs [12]. Chen et al. [7] established a chiral LC method for
the pharmacokinetics study of ornidazole after i.v. administration
of the racemic mixture and individual enantiomers in beagle
dogs. Ornidazole enantiomers were analyzed on a Chiralcel OB-H
column at 310 nm with a mobile phase consisting of hexane-
isopropyl alcohol-methyl t-butyl ether-glacial acetic acid (90:2:8:
0.5 v/v/v). Later, Wang et al. [3] developed a stereoselective LC
method to determine the enantiomers of ornidazole in human
plasma and urines sample using a Chiralcel OB-H column and
hexane-ethanol-glacial acetic acid (94:6:0.08, v/v/v). There is one
published paper describing an enantioseparation method with
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Fig. 1. Structure of levornidazole.
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isopropyl alcohol (95:4:1, v/v/v) to determine the enantiomeric
impurity in levornidazole injection and raw material [8]. The
elution time of this method is around 65 min. The enantiomeric
impurity was not detected in both valid levornidazole injection
and raw material. A chromatogram was shown of levornidazole
and its chiral impurity at 0.5% level which was not fully baseline
resolved. However, these days chiral CE can be considered as an
alternative technique to LC in terms of rapid analysis time, lower
buffer consumption, high efficiency and use of a wide variety of
chiral selectors. Cyclodextrins (CDs) and their derivatives remain
the most popular chiral selectors due to their water solubility,
stability in solution, UV transparency and ionizability. Chankvetadze
et al. [13] investigated the enantioseparation of some chiral
pharmaceuticals containing an imidazole (1,3-diazole) moiety,
including ornidazole, by using chiral CE. Various native CDs and
derivatized CDs were used as chiral buffer additives. As a hydro-
phobic phenyl moiety is absent in the ornidazole molecule, and, a
hydrophilic hydroxyl group is present, none of the used chiral
selectors used could resolve the enantiomers of ornidazole.
Recently, it has been reported that an enantioselective CE method
has been developed for racemic ofloxacin and ornidazole in
pharmaceutical formulations using 30 mg/mL of sulfated-b-CD
(S-b-CD) and a background electrolyte (BGE) of 50 mM phosphate
buffer [14]. The migration time of ornidazole is around 16 min
and LOQ is 3 mg/mL.
Since levornidazole has been brought to the pharmaceutical
market as a second generation single enantiomer drug, the quality
control and enantiomeric impurity control are highly required.
Therefore, in our study, a rapid and sensitive enantioseparation
CE method was developed for the analysis of levornidazole and its
chiral impurity at a 0.05% level. The method was further validated
based on ICH guidelines [15]. In addition, the method was applied
to bulk sample and injection formulations.2. Experimental
2.1. Chemicals
Ornidazole reference standard and levornidazole reference
standard were kindly donated by Jiangsu Institute for food and
drug control (Nanjing, China). Levornidazole bulk sample and
levornidazole sodium chloride injection (0.5 g/100 mL) were from
Nanjing sanhome pharmaceutical Co., Ltd (Nanjing, China). b-CD
and hydroxypropyl-b-CD (HP-b-CD) were purchased from Acros
organics (New Jersey, USA). Carboxymethyl-b-CD (CM-b-CD),
carboxyethyl-b-CD (CE-b-CD), methyl-b-CD and phosphate-b-CD
(P-b-CD) were acquired from Sigma Aldrich (St. Louis, USA). a-CD
and g-CD were obtained from Cyclolab (Budapest, Hungary).
Sulfobutylether-b-CD and sulfopropylated-b-CD (SP-b-CD) were
obtained from Biotium (Hayward, USA). S-b-CD and S-a-CD were
bought from Sigma Aldrich (Bornem, Belgium).Ortho-phosphoric acid 85% w/w and methanol, HPLC grade
were from VWR (Leuven, Belgium). Disodium hydrogen phos-
phate and sodium hydroxide were bought from Fisher Scientific
(Leicestershire, UK) and Tris was purchased from Applichem
(Darmstadt, Germany). All reagents were of analytical or LC grade.
The water used for preparing solutions was milli-Q water (Milli-
pore, Milford, Massachusetts, USA).
2.2. CE apparatus and conditions
All the experiments were carried out on a P/ACE MDQ capillary
electrophoresis system (Beckman Coulter Instruments, CA, USA)
equipped with a diode array UV–vis detector. An uncoated fused-
silica capillary (Polymicro Technologies, Phoenix, AZ, USA) of
50 mm i.d. and 60.2 cm total length (short end injection, 10.2 cm
effective length) was used. Short end injection was performed at
the cathodic side which is from the end of the capillary nearest
the detector. Instrument control and data evaluation were per-
formed using 32 Karat software (Beckman Coulter, version 5.0).
Unless stated otherwise online UV detection was performed at
277 nm, a voltage of 30 kV was applied and the capillary tem-
perature was controlled at 25 1C by liquid cooling. A Metrohm pH
meter was used after calibration (Herisau, Switzerland). Sample
solutions were introduced by pressure (0.5 psi) for 5 s. Every day,
before starting or after finishing the experiments, the capillary
should be washed with 0.1 M NaOH for 10 min, followed by H2O
for 10 min. Between each run, the rinsing procedure comprised
0.1 M NaOH for 2 min, then H2O for 2 min, followed by 3 min BGE.
2.3. Electrolyte and sample preparation
2.3.1. Background electrolyte
For the preparation of the BGE, 2.0% (w/v) S-a-CD was weighed
in a flask, dissolved and diluted with 20 mM Tris-phosphate
buffer (pH 2.1) to the volume. The 20 mM Tris phosphate buffer
was prepared by adding 1 M Tris to a phosphoric acid solution
until pH 2.1 was reached. The final phosphate concentration was
20 mM. Refresh the BGE solution after 12 runs.
2.3.2. Sample preparation
Levornidazole reference standard solution: 250.0 mg of the
reference substance and a certain amount of 2,4,6-triaminopyr-
imidine were transferred into a 50.0 ml flask. Dissolve and dilute
to volume with H2O.
Levornidazole sodium chloride injection solution: an appro-
priate amount of 2,4,6-triaminopyrimidine was dissolved in
50.0 mL of levornidazole sodium chloride solution. The sample
solution could be injected after filtration through a 0.2 mm pore
size filter.
2.4. Experimental design
A factorial analysis study was performed by means of an
experimental design and multivariate analysis using Modde
5.0 software (Umetrics, Umea˚, Sweden). A two level full factorial
design was used. The number of runs is equal to 2kþn, where k is
the number of parameters and n is the number of center points.
Three variables were investigated in this study including con-
centration of CD, concentration of the BGE and temperature of the
capillary. With the number of variables (k¼3) and 3 replicates of
the center point, 11 experiments were performed. The statistical
relationship between a response Y and the experimental variables
Xi, Xj, y is of the following form:
Y ¼ b0þbiXiþbjXjþbijXiXjþ . . .þE
X. Deng et al. / Talanta 106 (2013) 186–191188where the b’s are the regression coefficients and E is the overall
experimental error.
The linear coefficients, bi and bj, describe the quantitative
effect of the experimental variables in the model while the cross
coefficient bij measures the interaction effect between the vari-
ables i and j.3. Results and discussion
3.1. Method development
3.1.1. Screening of selectors
It is well known that the most important step of developing a
chiral CE method consists of choosing suitable chiral selectors. In
this study, several neutral CDs and negatively charged CDs were
screened at different pH values as potential selector candidates,
namely a-CD, b-CD, g-CD, CE-b-CD, HP-b-CD, SBE-b-CD, methyl-
b-CD, SP-b-CD, S-b-CD, S-a-CD, CM-b-CD and P-b-CD. After the
screening process, no neutral CDs could separate the ornidazole
enantiomers (500 mg/mL) at pH 2.0 in a normal polarity mode. On
the other hand, four kinds of charged CDs including SBE-b-CD, SP-
b-CD, S-b-CD and S-a-CD could give a baseline resolution in a
reverse polarity mode. For the enantioseparation with expensive
SBE-b-CD and SP-b-CD, large amounts were needed. As previously
reported, S-b-CD gave enantiomer separation at lower pH [14]
and it was seen in our study that levornidazole eluted before its
chiral impurity. However, when applying S-a-CD, the migration
order of the two enantiomers was changed, resulting in a good
order for an impurity control method with the impurity eluting
before the main peak. Moreover, the peak shapes of the two
enantiomers improved in comparison with employing S-b-CD and
the resolution (Rs) between both peaks was satisfactory. There-
fore, 2% of S-a-CD was chosen for further study.3.1.2. Choosing buffer pH and composition
Based on the nature and structure of ornidazole, the pKa value
is about 2.4 with a weakly basic imidazole group. Therefore, the
compound could be treated as a cation at lower pH. The buffer pH
was investigated from 1.5–3.1 with a constant 2% of S-a–CD.
Below pH 1.9, the baseline fluctuated which would influence the
method sensitivity. The problem was due to the lower pH causing
a high current. At pH 2.1, there was enough resolution between
the two enantiomers and the baseline became stable. When
increasing the pH from 2.4 to 3.1, ornidazole could not be
detected in reversed polarity mode. When applying normal
polarity, ornidazole migrated at 2 min, but without any separa-
tion. That is probably because the speed of EOF increased, which
carries the analytes–selector complex to the cathode. The high pH
also leads to lower interactions between analyte and chiral
selectors. The buffer co-ion is also a very important parameter
in CE methods since it not only has an influence on current
strength, but also represents a good way to avoid peak shape
distortions. If the electric field strength in the sample zone and
the electric field strength in the pure BGE zone are different, the
electrophoretic velocity of the analyte in the sample zone and in
the pure BGE zones will be different and lead to fronting or tailing
peaks [16]. This phenomenon is known as electromigration
dispersion. At a pH around 2, phosphate is the most effective
background buffer. Three co-ions, namely, sodium, potassium and
Tris, were examined and compared. In contrast to potassium and
sodium, Tris is a big molecule which migrates slowly and
produces less current. Considering that the pH of BGE is lower
and in order to avoid the Joule heating problem during later
investigation, Tris-phosphate buffer was used in our study.3.1.3. Short end injection
For an analytical method, the analysis time should be opti-
mized at the very beginning. This could save time for optimiza-
tion of other parameters during the method development phase
and also plays an important role when the method is used in
routine analysis. Usually, the two most convenient ways of
getting a rapid method are an increase of applied voltage and a
decrease of the capillary length. However, the maximum applied
voltage to be used in a commercial instrument is 30 kV and a
decrease of capillary length produces higher currents. A short end
injection could provide an extremely rapid analysis time without
any Joule heating problem. In this study, due to the strong
separation power of S-a-CD, Rs of the two enantiomers is large,
which provides a chance to perform short end injection.
A capillary of 60.2 cm long and 50 mm i.d. was used, and the
effective length was 10.2 cm. The ornidazole enantiomers were
injected from the end of the capillary nearest the detector giving a
total analysis time less than 6 min instead of 15 min for conven-
tional injections.
3.1.4. Buffer concentration
Buffer concentration determines the ionic strength of the BGE
and influences the buffer capacity. A range of 10–70 mM of Tris-
phosphate buffer was studied. The buffer capacity of the buffer is
determined by the actual amounts of acid and salt. A buffer made
with very little acid and salt will not have a great buffer capacity
while a higher buffer concentration can cause a Joule heating
problem. 20 mM Tris-phosphate buffer with short end injection
was finally used, because peak shapes, repeatability and electric
current remained satisfactory after 20 continuous injections.
3.1.5. Selector concentration
The CDs concentration influences the Rs of the two enantio-
mers and also has an effect on the migration time. A range from
1.0% to 4.0% of S-a-CD was taken for the study. Theoretically, a
higher CD concentration causes an increase of chiral resolution
with a maximum. In our case, levornidazole and its chiral
impurity in a ratio of 1:1000 (5000 mg/mL levornidazole and
5 mg/mL enantiomeric impurity) were used to investigate if Rs
was enough for chiral impurity control. Due to the limited
effective capillary length in short end injection, the Rs of the
enantiomers slowly increases from 2.0%–4.0%. However, the
current was observed to increase obviously. When the concentra-
tion of S-a-CD was 2.0%, the Rs was more than 5, which is enough
for determining the chiral impurity. The migration time is less
than 7 min.
3.1.6. Internal standard
Several compounds which could possibly migrate in front of
the two enantiomers, were tried as an IS. Finally, 2,4,6-triamino-
pyrimidine was selected since the migration time is around 1 min
and the peak shape was quite good. The stability of the IS will be
investigated.
3.2. Factorial analysis
The purpose of factorial analysis is to investigate the effect of a
certain range (indicated at 3 levels by lower, center and higher
level) of changes of electrophoretic parameters on target response
factors by means of an experimental design. The different elec-
trophoretic parameter settings in the design are concentration of
CDs (lower 1.5%, center 2%, higher 2.5%), BGE (lower 15 mM,
center 20 mM, higher 25 mM) always at pH 2.1, temperature
(lower 20 1C, center 25 1C, higher 30 1C). The investigated
responses included Rs between the two enantiomers, migration
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Fig. 2. (a) Regression coefficient plot of impurity peak ratio. (b) Regression
coefficient plot of Rs regression Experimental conditions: voltage: 30 kV, pH of
BGE: 2.1, short end injection: 5 s at 0.5 psi.
Table 1
Accuracy of levornidazole and enantiomeric impurity. Experimental conditions:
see Fig. 3.
Added (lg/mL) Amount found (lg/mL) Recovery %
X. Deng et al. / Talanta 106 (2013) 186–191 189time (tm) of levornidazole, theoretical plate number (N), current
value and the peak ratio (impurity peak/(levornidazole peakþ
impurity peak)). Fig. 2a shows the peak ratio response results
expressed as a regression coefficient plot. The plot consists of
bars, representing the regression coefficients. The bars with one
variable reflect the linear effect of that particular variable and the
bars with variable 1: variable 2 reflect the interaction between
two concerned variables. The line over bars stands for the error
(95% confidence interval). All error lines include zero, which
means the variation of peak ratio response factor is smaller than
the experimental error. Thus the peak ratio change caused by
changes of the three electrophoretic variables is considered not to
be significant. All the other response factors except Rs were
considered to be not significantly influenced by the variables.
For Rs (Fig. 2b), it shows that when increasing the CD concentra-
tion, Rs increased. However, using 2% (w/v) of CD gave a
satisfactory Rs between levornidazole and its chiral impurity. So,
improving Rs was not necessary.
3.3. Validation
Validation was performed based on ICH guidelines [15] in
terms of linearity, quantitation limit, detection limit, accuracy and
precision. The stability of solutions and CD batch effect were also
investigated in this section.Levornidazole
4000.0 4140.0 103.5
5000.0 5025.0 100.5
6000.0 6462.0 105.2
Enantiomeric impurity
1 1.02 102.0
5 5.05 101.0
8 8.22 102.73.3.1. LOD and LOQ
The LOD of ornidazole is determined as the concentration
yielding a signal three times the noise of the baseline, which in
this case equals 0.3 mg/mL (0.006%). The LOQ, which is calculated
as ten times the noise, equals 1.0 mg/mL (0.02%). The sensitivity is
better than previous one using S-b-CD [14].3.3.2. Linearity
Since we aimed to develop a method performing assay and
purity together as one test, linearity should cover the range from
the reporting level of the impurities to 120% of the assay
specification. Thus, a calibration curve was constructed with six
concentrations corresponding to 2.5, 25, 250, 500, 2500, 6000 mg/mL
of levornidazole. Each concentration was injected three times. The
regression line was calculated by the method of least squares:
y¼0.0015xþ0.0304. Zero was included in the 95% confidence
interval of the intercept and the square of the correlation
coefficient (R2) is 0.9999. A residual sum of squares plot was also
performed and the residuals were normally scattered around the
0 line.3.3.3. Accuracy
A recovery test could be assessed on placebo spiked with
known amounts of active pharmaceutical ingredient (API) and
chiral impurity. Recovery tests of levornidazole and chiral impur-
ity were performed at three different concentration levels. Based
on the label of levornidazole injection solution, the placebo
solution was prepared by dissolving a certain amount of sodium
chloride in water used for preparation of injection formulations,
and adjusting the pH to 3.2 with 1 M hydrochloric acid. Since no
pure chiral impurity sample was available, ornidazole containing
equal amounts of levornidazole and chiral impurity was used to
perform the recovery test of enantiomeric impurity. Thus, sam-
ples were prepared by dissolving a known quantity of levornida-
zole reference and ornidazole reference in an amount of placebo.
9 determinations were performed at three concentrations corre-
sponding to 4000, 5000 and 6000 mg/mL of levornidazole and
1 mg/mL, 5 mg/mL and 8 mg/mL of chiral impurity, respectively.
With respect to the major analyte, chiral impurity equals 0.02%,
0.1% and 0.16% of levornidazole. Results are shown in Table 1.3.3.4. Precision
Intraday precision can be deduced from determinations of
accuracy. The interday precision was collected over three days (9
determinations at higher, middle and lower concentrations for
chiral impurity and levornidazole). The results of interday preci-
sion and intraday precision are shown in Table 2.3.3.5. CD batches effect test
The commercially available S-a-CD consists of numerous
isomers, which vary by their substitution degree and also site of
substitution. Batch to batch difference may result in different
mobility and selectivity, while sometimes, poor reproducibility.
In our study, two batches of S-a-CD (batch No. MKBH3350 and
MKBD6277) were compared. Rs between the two enantiomers
was calculated and compared by a t-test (95% confidence level).
It can be concluded that there was no statistically significant
difference in resolution yielded by the two batches.
Table 2
Intraday and interday precision. Experimental conditions: see Fig. 3.
Concentration
(mg/mL)
Intraday precision RSD (%)
(from accuracy data)
Interday precision RSD (%)
(performed using reference)
Levornidazole
4000 0.6 2.3
5000 2.4 2.8
6000 1.7 1.1
Chiral impurity
1 2.6 4.0
5 3.4 3.1
8 3.6 3.1
Table 3
Assay values for several batches of levornidazole
raw materials and injections. Experimental condi-
tions: see Fig. 3.
Assay (%)
Batches of injections
201011021 100.0
200912041 100.5
201003171 101.3
201201091 100.3
Batches of raw materials
20091001 99.9
20100501 100.6
20100502 101.4
200906301 101.5
1 2 3 4 5 6
AU
0.000
0.001
0.002
0.003
0.004
0.005
0.006
IS
Enantiomeric
impurity
Levornidazole
Minutes
0 2 4 6
AU
0.000
0.005
0.010
0.015
0.020
0.025
Levornidazole
Enantiomeric impurity
Minutes
IS
Fig. 3. Typical electropherogram of 5 mg/mL levornidazole injection solution
spiked with 2.5 mg/mL enantiomeric impurity (0.05%) (a) full size, (b) enlarged
view. Experimental conditions: BGE: 20 mM Tris-phosphate buffer containing
2.0% (w/v) S-a-CD at pH 2.1, voltage: 30 kV, temperature: 25 1C, short end
injection: 5 s at 0.5 psi.
X. Deng et al. / Talanta 106 (2013) 186–1911903.3.6. Stability of sample solution
Freshly prepared stock solutions of levornidazole (5000 mg/mL)
were compared to 15 days old ones stored at 5 1C in brown
bottles. There was no significant difference of relative corrected
peak area between fresh and old solutions compared by a t-test
(95% confidence level). However, to avoid possible interaction
with the IS, the IS was prepared freshly and added into the stock
solution just before the experiments were performed.
3.3.7. Selectivity
A blank test was performed by checking injection placebo
solution. There was no interference. In addition, there was also no
interference at different peak sections for levornidazole by using
DAD.
3.4. Quantitative results
3.4.1. Assay of levornidazole in injection solution
All calculations on the sample solutions are performed with
reference solutions injected prior to the sample solutions. For
each batch, two preparations of sample were injected to get three
determinations for each. Results are shown in Table 3.
3.4.2. Determination of enantiomeric impurity in injection solution
In order to investigate the capability of developed method,
several batches of levornidazole raw materials and injections
were tested. No chiral impurity could be detected in injection
solution sample (0.5 g/100 mL) or raw materials. When spiking
5 mg/mL racemic ornidazole, which corresponded to 0.05% of
levornidazole into injection sample solution, the chiral impurity
could be detected and quantified by internal normalization.
Fig. 3a shows a typical electropherogram of 5 mg/mL levornida-
zole and sodium chloride injection solution spiked with 2.5 mg/mL
enantiomeric impurity (0.05%). It proves that if chiral impurity is
present in the sample solution at a level of 0.05%, the developedmethod can be applied to quantify the chiral impurity and
perform the assay simultaneously.4. Concluding remarks
A sensitive and rapid chiral CE method was developed for
levornidazole. Applying short end injection, total analysis time is
around 7 min, which is much faster than the existing chiral LC
method [8]. After validation, the method could be applied to the drug
substance and injection solution for the simultaneous determination
of levornidazole and its enantiomeric impurity.
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